These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23409080)

  • 1. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.
    Kewitz S; Staege MS
    PLoS One; 2013; 8(2):e55897. PubMed ID: 23409080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia.
    Steinbach D; Pfaffendorf N; Wittig S; Gruhn B
    Cancer Genet Cytogenet; 2007 Aug; 177(1):51-4. PubMed ID: 17693191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.
    Epping MT; Wang L; Edel MJ; Carlée L; Hernandez M; Bernards R
    Cell; 2005 Sep; 122(6):835-47. PubMed ID: 16179254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs.
    Staege MS; Banning-Eichenseer U; Weissflog G; Volkmer I; Burdach S; Richter G; Mauz-Körholz C; Föll J; Körholz D
    Exp Hematol; 2008 Jul; 36(7):886-96. PubMed ID: 18400362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).
    Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J
    Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
    De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
    Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
    Oehler VG; Guthrie KA; Cummings CL; Sabo K; Wood BL; Gooley T; Yang T; Epping MT; Shou Y; Pogosova-Agadjanyan E; Ladne P; Stirewalt DL; Abkowitz JL; Radich JP
    Blood; 2009 Oct; 114(15):3299-308. PubMed ID: 19625708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
    Lee YK; Park UH; Kim EJ; Hwang JT; Jeong JC; Um SJ
    Cancer Lett; 2017 Sep; 403():144-151. PubMed ID: 28634046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.
    Hermes N; Kewitz S; Staege MS
    Curr Cancer Drug Targets; 2016; 16(5):400-14. PubMed ID: 26694250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma.
    Ercolak V; Paydas S; Bagir E; Ergin M; Seydaoglu G; Celik H; Yavu B; Tanriverdi K; Gunaldi M; Afsar CU; Duman BB
    Acta Haematol; 2015; 134(4):199-207. PubMed ID: 26044287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses.
    Winkler C; Steingrube DS; Altermann W; Schlaf G; Max D; Kewitz S; Emmer A; Kornhuber M; Banning-Eichenseer U; Staege MS
    Cancer Immunol Immunother; 2012 Oct; 61(10):1769-79. PubMed ID: 22419371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
    Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
    Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.
    Tanaka N; Wang YH; Shiseki M; Takanashi M; Motoji T
    Leuk Res; 2011 Sep; 35(9):1219-25. PubMed ID: 21550659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of the hypoxia pathway modulates chemotherapy resistance in Hodgkin's lymphoma cells.
    Kewitz S; Kurch L; Volkmer I; Staege MS
    Tumour Biol; 2016 Jun; 37(6):8229-37. PubMed ID: 26718211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRAME promotes in vitro leukemia cells death by regulating S100A4/p53 signaling.
    Xu Y; Rong LJ; Meng SL; Hou FL; Zhang JH; Pan G
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1057-63. PubMed ID: 27049257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor antigen PRAME is a potential therapeutic target of p53 activation in melanoma cells.
    Lee YK; Heo HH; Kim N; Park UH; Youn H; Moon EY; Kim EJ; Um SJ
    BMB Rep; 2024 Jun; 57(6):299-304. PubMed ID: 38835116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of NADPH-cytochrome P450 reductase on all-trans-retinoic acid efficacy and cytochrome P450 26A1 expression in human myeloid leukaemia HL-60 cells.
    Hu L; Lv JF; Zhuo W; Zhang CM; Zhou HH; Fan L
    J Pharm Pharmacol; 2016 Sep; 68(9):1193-202. PubMed ID: 27366899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia.
    Ozpolat B; Mehta K; Tari AM; Lopez-Berestein G
    Am J Hematol; 2002 May; 70(1):39-47. PubMed ID: 11994980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione-S-transferases and Chemotherapy Resistance of Hodgkin's Lymphoma Cell Lines.
    Bernig T; Ritz S; Brodt G; Volkmer I; Staege MS
    Anticancer Res; 2016 Aug; 36(8):3905-15. PubMed ID: 27466493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma.
    Kawano R; Karube K; Kikuchi M; Takeshita M; Tamura K; Uike N; Eto T; Ohshima K; Suzumiya J
    J Clin Exp Hematop; 2009 May; 49(1):1-7. PubMed ID: 19474511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.